Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
To determine the pharmacokinetic profile and safety of udenafil in adolescents with Fontan
physiology and to assess the short-term pharmacodynamic effect of udenafil on pharmacodynamic
measures of exercise capacity, ventricular performance, and vascular function.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Mezzion Pharma Co. Ltd
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) Pediatric Heart Network